Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content|Head and Neck Cancer Squamous Cell Carcinoma|Non-small Cell Lung Cancer|Gastric Cancer|Esophageal Cancer|Pancreas Cancer|Bladder Cancer|Renal Cell Carcinoma|Melanoma|Triple-negative Breast Cancer|Ovarian Cancer|Colo-rectal Cancer|Fallopian Tube Cancer
Interventions: DRUG: ADCT-301|BIOLOGICAL: Pembrolizumab
Sponsor: ADC Therapeutics S.A.